The effect of protease inhibitor‐based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART‐naïve patients with HIV‐infection

Objectives To assess the effect of protease inhibitor (PI)‐based dual therapy on CD4/CD8 ratio during the first year of therapy in antiretroviral therapy (ART)‐naïve patients using data from randomized controlled clinical trials. Methods We pooled data from the GARDEL and ANDES studies, both randomi...

Full description

Saved in:

Bibliographic Details
Published in:	HIV medicine Vol. 22; no. 4; pp. 254 - 261
Main Authors:	Figueroa, MI, Camiro‐Zuñiga, A, Belaunzaran‐Zamudio, PF, Sierra Madero, J, Andrade Villanueva, J, Arribas, JR, Lama, JR, Cecchini, DM, Lopardo, G, Crabtree‐Ramírez, B, Gun, A, Patterson, P, Fink, VI, Sued, OG, Cahn, P
Format:	Journal Article
Language:	English
Published:	England Wiley Subscription Services, Inc 01-04-2021
Subjects:	Anti-HIV Agents Antiretroviral agents Antiretroviral therapy CD4 antigen CD4 Lymphocyte Count CD4‐CD8 ratio CD8 antigen CD8-Positive T-Lymphocytes Chi-square test Clinical trials Darunavir dual therapy HIV HIV Infections - drug therapy HIV Protease Inhibitors HIV-1 Human immunodeficiency virus Humans Lamivudine Lamivudine - therapeutic use Lopinavir Middle Aged Patients Protease Protease inhibitors Proteinase inhibitors Reverse Transcriptase Inhibitors Ritonavir Ritonavir - pharmacology Ritonavir - therapeutic use Statistical tests Subgroups Therapy Viral Load Lamivudine Darunavir CD4-CD8 ratio Lopinavir dual therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Objectives To assess the effect of protease inhibitor (PI)‐based dual therapy on CD4/CD8 ratio during the first year of therapy in antiretroviral therapy (ART)‐naïve patients using data from randomized controlled clinical trials. Methods We pooled data from the GARDEL and ANDES studies, both randomized controlled clinical trials that recruited ART‐naïve people living with HIV and randomly assigned them to receive PI‐based dual therapy (DT) or triple therapy (TT) aiming to compare viral efficacy. We compared median CD4/CD8 ratios and the proportion of patients with CD4/CD8 ratio > 1 at 48 weeks after ART initiation in both treatment arms using the Mann–Whitney U‐test and the χ2 test. We performed subgroup analysis for patients > 50 years old, with baseline CD4 counts ≤ 200 cells/μL, viral load > 100 000 HIV RNA copies/mL, and ritonavir‐boosted lopinavir‐based therapy. Results We analysed data from 571 patients: 292 on DT and 279 on TT. No differences were observed in CD4/CD8 ratio (0.632 vs. 0.617, P = 0.729) or in the proportion of patients with CD4/CD8 ratio > 1 (17.9% vs. 19.3%, P = 0.678) 48 weeks after ART initiation. Subgroup analysis showed no further differences. Conclusion The impact of PI‐based DT regimens on the CD4/CD8 ratio during the first year of treatment for ART‐naïve patients is similar to that of TT.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1464-2662 1468-1293
DOI:	10.1111/hiv.13008